Courses

This CME/CE program is derived from content presented as part of a larger rheumatology state meeting lecture series. The expert faculty, Dr. Dinesh Khanna, will first discuss the history of systemic sclerosis-associated interstitial lung disease, including prevalence, predictors of progressive ILD and screening. Following, recent clinical trial data in the interstitial lung disease treatment landscape will be reviewed, encompassing both ...
View Course

This CME/CE webcast, chaired by Fred D. Lublin, MD, will analyze current best practices for utilizing fumarate-based therapeutics to improve outcomes in patients with multiple sclerosis (MS). The expert faculty will first review the mechanism of action and targets of fumarates in the MS treatment landscape. Following, current trial data of fumarate-based therapeutics in MS will be reviewed and clinical ...
View Course

This CME activity is derived from content presented at the 7^th Annual European Stroke Organization Conference (ESOC) 2021 Virtual. The expert faculty, led by Dr. Stephan Mayer, will first provide an overview of double antiplatelet therapy, including pathobiology, disease mechanisms and platelet activation. Following, clinical trial data in stroke and cardiovascular disease will be reviewed. Next, the pros and cons ...
View Course

This CME/CE symposium is derived from content presented at the Congress of Clinical Rheumatology East Meeting and will highlight recent advances in the treatment and management of patients with interstitial lung disease (ILD). The expert faculty, Drs. Dinesh Khanna and Kevin Flaherty, will first review best practices for screening and diagnosing patients. Following, recent clinical trial data of both emerging ...
View Course

In this module, Jamie Faber, PA-C, along with Scott Kopetz, MD, PhD, course chair, will first delve into the practical considerations of biomarker testing for the interprofessional team. The expert faculty will also provide an overview of ctDNA, including the clinical implications in the colorectal cancer landscape. Following, best practices for managing adverse events to improve patient outcomes will be ...
View Course

In this module, Michael Sangmin Lee, MD, along with Scott Kopetz, MD, PhD, course chair, will review data presented at the ESMO World Congress on Gastrointestinal Cancer 2021 Meeting. The faculty will outline a few key studies from the meeting, focusing on populations such as those who were previously untreated and patients who received prior bevacizumab treatment. Current topics such ...
View Course

In this module, Michael Overman, MD, along with Scott Kopetz, MD, PhD, course chair, will highlight information presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The faculty will first analyze data regarding frontline metastatic colorectal cancer (mCRC), including the Keynote 177 and FOCUS 4N studies. Following, updates for both second-line mCRC and refractory mCRC therapeutics will ...
View Course

In this module, Benny Johnson, DO, along with Scott Kopetz, MD, PhD, course chair, will analyze targeted therapeutic options for BRAF-mutated metastatic colorectal cancer, with a focus on combination therapies. The faculty will highlight the pathway to precision therapy for BRAFV600E mutant metastatic colorectal cancer (mCRC), debating the clinical implications of recent trial data in an interactive panel format. Upon ...
View Course

In this module, Christopher Lieu, MD, along with Scott Kopetz, MD, PhD, course chair, will first discuss the current landscape of genomic testing for metastatic colorectal cancer (mCRC), highlighting the changes in the last decade. Following, the faculty will analyze testing options, covering topics such as gene sequencing, genomic profiling and liquid biopsy and circulating tumor DNA. To conclude, the ...
View Course

This CME/CE activity will highlight novel treatment strategies for sphingosine-1-phosphate (S1P) therapeutics to manage patients with moderate to severe ulcerative colitis (UC). The expert faculty, led by Dr. David T. Rubin, will first review the need for new therapeutics in ulcerative colitis, including treatment goals and unmet needs. Next, the faculty will analyze the science of S1P receptor modulators as ...
View Course